TUSTIN, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Radient Pharmaceuticals Corporation (NYSE Amex: RPC), (formerly AMDL, Inc.), a US-based integrated pharmaceutical company, announced today it has fully completed its corporate name change to Radient Pharmaceuticals Corporation and is now trading on the NYSE Amex under the ticker symbol "RPC". About Radient Pharmaceuticals: Radient Pharmaceuticals is a US-based pharmaceutical company headquartered in Tustin, CA. The Company researches, develops, manufactures and sells a portfolio of in vitro diagnostic (IVD) and high-end skin care products. More information can be found at http://www.radient-pharma.com/. Forward Looking Statements: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Radient Pharmaceuticals Corporation Contact: Kristine Szarkowitz Director-Investor Relations (Tel :) 206.310.5323 DATASOURCE: Radient Pharmaceuticals Corporation CONTACT: Kristine Szarkowitz, Director-Investor Relations of Radient Pharmaceuticals Corporation, +1-206-310-5323, Web Site: http://www.radient-pharma.com/

Copyright